{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:23:26Z","timestamp":1790504606396,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["19ZR1467900"],"award-info":[{"award-number":["19ZR1467900"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["20ZR1468100"],"award-info":[{"award-number":["20ZR1468100"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013279","name":"National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology","doi-asserted-by":"publisher","award":["2018ZX09711002-011-018"],"award-info":[{"award-number":["2018ZX09711002-011-018"]}],"id":[{"id":"10.13039\/501100013279","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejmech.2022.114519","type":"journal-article","created":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T03:50:20Z","timestamp":1654919420000},"page":"114519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Design and development of a novel series of oral bivalent BET inhibitors with potent anticancer activities"],"prefix":"10.1016","volume":"239","author":[{"given":"Menglan","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiajuan","family":"Huan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changqing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehong","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114519_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.005","article-title":"Bromodomains: structure, function and pharmacology of inhibition","volume":"106","author":"Ferri","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114519_bib2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S1097-2765(03)00035-2","article-title":"Bromodomains mediate an acetyl-histone encoded antisilencing function at heterochromatin boundaries","volume":"11","author":"Ladurner","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2022.114519_bib3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41573-019-0030-7","article-title":"Bromodomains: a new target class for drug development","volume":"18","author":"Cochran","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114519_bib4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.bbagrm.2014.03.011","article-title":"The bromodomain: from epigenome reader to druggable target","volume":"1839","author":"Sanchez","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2022.114519_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174523","article-title":"Bromodomains: a novel target for the anticancer therapy","volume":"911","author":"Gokani","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114519_bib6","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2217\/epi.14.91","article-title":"Targeting BET bromodomains for cancer treatment","volume":"7","author":"Jung","year":"2015","journal-title":"Epigenomics"},{"key":"10.1016\/j.ejmech.2022.114519_bib7","doi-asserted-by":"crossref","first-page":"7801","DOI":"10.1021\/acs.jmedchem.6b00070","article-title":"Optimization of a series of bivalent triazolopyridazine based bromodomain and extraterminal inhibitors: the discovery of (3r)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)","volume":"59","author":"Bradbury","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114519_bib8","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/nchembio.2210","article-title":"Potent and selective bivalent inhibitors of BET bromodomains","volume":"12","author":"Waring","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114519_bib9","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/nchembio.2209","article-title":"Design and characterization of bivalent BET inhibitors","volume":"12","author":"Tanaka","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114519_bib10","doi-asserted-by":"crossref","first-page":"7949","DOI":"10.1073\/pnas.1720000115","article-title":"Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth","volume":"115","author":"Ren","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2022.114519_bib11","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1021\/acsmedchemlett.0c00294","article-title":"Identification of 3,5-dimethylisoxazole derivatives as BRD4 inhibitors for the treatment of colorectal cancer","volume":"11","author":"Yang","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114519_bib12","doi-asserted-by":"crossref","first-page":"8642","DOI":"10.1021\/acs.jmedchem.9b01094","article-title":"Structure-based discovery and development of a series of potent and selective bromodomain and extra-terminal protein inhibitors","volume":"62","author":"Hu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114519_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/2159-8290.CD-17-0605","article-title":"BET proteins as targets for anticancer treatment","volume":"8","author":"Stathis","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2022.114519_bib14","article-title":"Safety and efficacy of bromodomain and extra-terminal inhibitors for the treatment of hematological malignancies and solid tumors: a systematic study of clinical trials","volume":"11","author":"Sun","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114519_bib15","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1158\/1078-0432.CCR-19-0578","article-title":"First-in-Human study of mivebresib (ABBV-075), an oral pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed\/refractory solid tumors","volume":"25","author":"Piha-Paul","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114519_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114435","article-title":"Novel bivalent BET inhibitor N2817 exhibits potent anticancer activity and inhibits TAF1","volume":"185","author":"Wu","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114519_bib17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41419-019-1793-9","article-title":"Inhibition of the BET family reduces its new target gene Ido1 expression and the production of L-kynurenine","volume":"10","author":"Tian","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2022.114519_bib18","doi-asserted-by":"crossref","first-page":"8369","DOI":"10.1021\/acs.jmedchem.7b00746","article-title":"Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075\/Mivebresib), a potent and orally available bromodomain and extraterminal domain (BET) family bromodomain inhibitor","volume":"60","author":"McDaniel","year":"2017","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422004214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422004214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:39:47Z","timestamp":1759329587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422004214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":18,"alternative-id":["S0223523422004214"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114519","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and development of a novel series of oral bivalent BET inhibitors with potent anticancer activities","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114519","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114519"}}